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Sixteen percent (n = 3,025) of the caregivers had a child with an ASD diagnosis. 
As compared to caregivers of children with MHC only, caregivers of children with 
ASD were significantly more likely to report issues with availability (AOR = 2.16, 
95% CI = 1.66-2.82), information (AOR = 1.89, 95% CI = 1.46-2.45), eligibility (AOR = 
1.80, 95% CI = 1.38-2.37), cost (AOR = 1.67, 95% CI = 1.31-2.14), and appointments 
(AOR = 1.35, 95% CI = 1.09-1.68). When compared to the DD & MHC group, the 
ASD group was found to be significantly more likely to report issues with 
availability, obtaining information, and cost of services. CONCLUSIONS: ASD 
caregivers reported greater difficulty with all five service difficulty measures as 
compared to caregivers of children with MHC only. However, ASD group reported 
greater problems only in availability, obtaining information, and cost of services, 
when compared to DD & MHC group.  
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GEOGRAPHIC VARIATION IN DIAGNOSIS, MEDICATION USE AND ASSOCIATED 
COSTS OF ATTENTION DEFICIT DISORDER (ADD)  
Tian Y, Frazee SG, Henderson RR, Iyengar R 
Express Scripts, Inc., St. Louis, MO, USA  
OBJECTIVES: To use administrative claims to examine geographic variation 
trends in ADD diagnostic prevalence, medication use and associated medical and 
pharmacy costs. METHODS: A retrospective design and descriptive analysis of 
continuously enrolled (medical and pharmacy benefits) commercial members 
aged four to 40 between January 1, 2008 and December 31, 2010 from 
MarketScan®Commercial Claims and Encounters dataset. Key metrics included 
percent of continuously enrolled patients with ADD diagnosis, patients with ADD 
medication use and associated pharmacy and medical costs per enrollee. ADD 
diagnosis was defined as having a medical diagnostic code (ICD9) of 3140 at any 
time during a given year. Medication use was defined as having at least one 
claim for amphetamines, attention-deficit/hyperactivity-disorder agents or 
stimulants. RESULTS: The datasets comprised of 11.8, 12 and 13 million enrollees 
in 2008, 2009 and 2010, respectively. Results indicate that although the diagnostic 
prevalence, medication use and associated medical and pharmacy costs were 
the highest in the South throughout the study period, Northeast region had the 
highest growth rate. Increasing by 34.1% from 1.9% to 2.5% for patients 
diagnosed and by 43.0% from 2.4% to 3.5% for patients treated with ADD 
medications. Growing at rate of 59.0% from $34.21 in 2008 to $54.39 in 2010, 
Northeast outpaced the other regions by more than 24.1% on ADD related 
medical and pharmacy spend per enrollee. CONCLUSIONS: Northeast is the 
fastest growing region for ADD diagnosis, medication use and related spend. 
Further research is warranted to examine the factors underlying this trend. The 
findings suggest consideration of utilization management programs and cost 
containment strategies to ensure appropriate access, patient safety and cost-
effective use of ADD medications.  
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HOSPITALIZATIONS AMONG BIPOLAR DISORDER PATIENTS BEFORE AND 
AFTER INITIATING LURASIDONE IN A COMMERCIALLY INSURED  
POPULATION  
Hassan M1, Wade SW2, Meyer NM3, Pikalov A1, Loebel A4, Rajagopalan K1 
1Sunovion Pharmaceuticals, Inc., Marlborough, MA, USA, 2Wade Outcomes Research and 
Consulting, Salt Lake City, UT, USA, 3Truven Health Analytics, Cambridge, MA, USA,  
4Sunovion Pharmaceuticals, Inc., Fort Lee, NJ, USA  
OBJECTIVES: Bipolar disorder is a costly severe mental illness with high rates of 
hospitalizations compared to several other behavioral disorders. This study aims 
to compare all-cause and mental health-related hospitalizations among adult 
patients with bipolar disorder 6-months before and after initiating lurasidone, an 
atypical antipsychotic agent. METHODS: A retrospective analysis of health 
insurance claims from the Truven Health MarketScan Commercial Database was 
conducted. The study population included individuals ages 18–64, who initiated 
lurasidone between October 1, 2010 to September 30, 2011 (initiation date=index), 
had ≥ 1 inpatient or ≥ 2 outpatient medical claims with an ICD-9-CM diagnosis 
code for bipolar disorder and had continuous health benefit coverage during the 
study period. All-cause hospitalizations and mental health-related 
hospitalizations associated with a primary diagnosis code for a mental health 
disorder were evaluated for the 6-months pre- and post-index date. Proportions 
of patients with hospitalizations and mean number of hospitalizations were 
compared using chi-square and paired t-test, respectively. RESULTS: The study 
population (N=234) was predominantly female (68.8%) with a mean age of 41.6 
years. Common pre-index comorbidities included depression (61.5%), anxiety 
(24.4%), hypertension (20.5%) and diabetes (20.1%). The proportion of patients 
with all-cause hospitalizations decreased from 33.3% in the pre-period to 21.4% 
in the post-period (p = 0.0005). Similarly, the proportion of patients with mental 
health-related hospitalizations decreased from 27.8% to 17.1% between the pre-
and post-index periods (p=0.0006). The mean numbers of hospitalizations in the 
pre- and post-index periods were 0.6 and 0.3 for all-cause (p=0.0175) and 0.5 and 
0.2 for mental health-related conditions (p=0.0310). CONCLUSIONS: In this 
analysis of patients with bipolar disorder, significantly smaller proportions of 
patients were hospitalized for all-cause and mental health-related diagnoses in 
the 6 months after initiating lurasidone compared to the 6 months before 
initiation. The mean numbers of hospitalizations were also significantly lower in 
the 6-months after initiation on lurasidone.  
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THE MEDICAL COSTS AND HEALTH CARE UTILIZATION FOR DEPRESSION 
TREATMENT BY KOREAN HEALTH INSURANCE REVIEW & ASSESSMENT 
SERVICE DATA  
Kim CM1, Lee YJ2, Eun Y2, Heo S2, Choi WS2 
1Catholic University College of Medicine, Seoul, South Korea, 2Catholic University, Seoul, South 
Korea  
OBJECTIVES: To investigate the use of health care utilizations and direct medical 
costs for patients with depression. METHODS: This study combined major 
clinical information of 1183 depressed patients who registered for the 
prospective depressed patients cohort study (CRESCEND: the Clinical Research 
Center for Depression Study) from January 2006 to August 2008 and the health 
insurance claims filed with the Health Insurance Review & Assessment Service, 
HIRA. Of these patients, 834 who had HAMD-17 scores > 14 at screen visit and 
more than one time claim for reimbursement of antidepressants at HIRA after 
their cohort enrollment were subject to this analysis on their use of health care 
institutions, in-patient and out-patient, as well as their medical costs. RESULTS: 
The hospital visit by out-patients with depression was 17.3 times a year with the 
average hospitalization rate at 20.9%. The times of hospital visits tended to 
increase in cases of elderly patients, patients with comorbidities, patients 
treated with combination therapy, patients prescribed with NADs and patients 
treated with multiple drugs in combination. The hospitalization rate tended to 
increase in cases of patients with comorbidities, severer patients in HAMD 
scores, patients treated with combination therapy, Patients prescribed with 
NADs and patients treated with multiple drugs in combination. In direct medical 
costs, drug expenses represented 60.6%. The costs tended to increase in elderly 
patients, patients with comorbidities, severer patients in HAMD scores, 
combination therapy patients, patients prescribed with NADs than SSRI and 
patients prescribed with multiple drugs. Drug expenses increased with the rise 
in out-patient visits, and medical costs at 12 months increased in out-patients 
with less hospital visits. CONCLUSIONS: SSRIs are first-line treatment to save 
direct medical costs. HAMD is regarded as the most relevant measure not only 
for the severity of depression but also for the estimation of the use of health care 
institutions and medical costs.  
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IMPACT OF TREATMENT PERSISTENCE ON HEALTH CARE CHARGES AMONG 
OPIOID-DEPENDENT PATIENTS TREATED WITH BUPRENORPHINE/NALOXONE: 
2006-2012 INSURANCE CLAIMS RETROSPECTIVE ANALYSIS IN THE UNITED 
STATES  
Clay E1, Khemiri A2, Ruby J3, Zah V4, Aballea S1 
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Tunis, Tunisia, 3Reckitt Benckiser 
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OBJECTIVES: Buprenorphine/naloxone combination (BUP/NAL) is recommended 
in the treatment of opioid dependence. Clinical guidelines do not specify the 
minimum duration of treatment required to achieve long-term remission. This 
study evaluated the impact of treatment persistence on health care charges. 
METHODS: Study was conducted on a US insurance claims database. It included 
patients initiating treatment with BUP/NAL claim between November 2006 and 
December 2011, not previously treated with buprenorphine, with at least one 
repeat claim after 30 days. Discontinuation was defined as absence of BUP/NAL 
claim for 90 days. Health care charges over 12 months were compared between 
persistent and non-persistent patients, adjusting on baseline characteristics 
(demographics, comorbidities, treatment, and resource utilization before index 
date). RESULTS: Of 19,008 patients with an incident claim of BUP/NAL, 35.7% 
appeared to be short-term users and were excluded. Among the remaining 
12,231 patients, the average duration of follow-up was 12.9 months, and 2846 
were followed for at least two years. The probability of continuing treatment 
over 24 months was 40.9%. Patients under 25 years old, with a diagnosis of 
hepatitis or soft tissue infection were more likely to discontinue. Patients treated 
for at least 12 months had lower mean total charges compared to non-persistent 
patients ($22,912 vs. $31,687; p<0.0001), adjusting on baseline characteristics. 
Among non-persistent patients, total charges per quarter reached a maximum 
during the first trimester following discontinuation (+91% compared to period 
from 6 to 4 months before discontinuation, p<0.0001), and were also significantly 
higher in the second trimester after discontinuation (+52%, p=0.0003), compared 
with before discontinuation. Main drivers of excess charges were hospitalization 
and outpatient visits. Majority of long-term users of BUP/NAL discontinued 
treatment before 24 months. CONCLUSIONS: Non-persistence was associated 
with higher charges and evidence was consistent with a causal relationship 
between discontinuation and increased charges. Treatment persistence 
improvement may lead to cost savings.  
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ASSESSING THE IMPACT OF A MEDICAID PRIOR AUTHORIZATION (PA) POLICY 
FOR DULOXETINE ON ANTIPSYCHOTIC USE AMONG PATIENTS WITH 
DEPRESSION  
Birnbaum HG1, Ivanova JI2, Waldman T1, Swallow E1, Cummings AK1, Clark T3, Peng X3, 
Swindle R3 
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Inc., New York, NY, USA, 3Eli Lilly and 
Company, Indianapolis, IN, USA  
OBJECTIVES: To evaluate if the Iowa Medicaid duloxetine depression Prior 
Authorization (PA) policy, implemented may 24, 2010, inadvertently increased 
atypical antipsychotic use in depressed patients. We compare initiations of 
duloxetine and other relevant medications for depression in Iowa before  
and after PA implementation and in Missouri, which had no duloxetine  
PA. METHODS: Using de-identified Iowa and Missouri Medicaid claims data 
(1999-2010), two cohorts were selected from each state: 2010 policy change 
cohort (index date: 5/24/2010) and 2009 control cohort (index date: 5/24/2009). 
Patients had to have ≥1 inpatient or 2 other medical claims with a depression 
diagnosis pre-index; ≥1 antidepressant or antipsychotic claim during the  
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six months pre-index (“baseline period”); and age<65 for six months post-index 
(“study period”). Baseline characteristics and study period prescription  
drug initiations (requiring six-month washout) by PA status (Iowa PA policy 
begun 5/24/2010) were compared between the two cohorts in each state. Logistic 
models were used to calculate risk-adjusted study period drug initiation rates, 
controlling for baseline characteristics. RESULTS: Iowa patients had significantly 
(p<.05) higher rates of anxiety and lower baseline health care costs 2010 versus 
2009 (n=9,429 vs. n=8,443). Missouri patients were significantly younger, had 
higher rates of mental disorders, and higher baseline health care costs in 2010 
versus 2009 (n=19,541 vs. n=13,083). In Iowa, risk-adjusted initiations  
of antidepressants (2009-2010) without PA increased significantly (17.8% vs. 
19.4%); initiations decreased significantly for: duloxetine (2.0% vs.1.6%), other 
antidepressants with PA (4.2% vs. 1.2%), and atypical antipsychotics without  
PA (7.5% vs. 6.7%). In Missouri, initiations increased significantly (2009-2010)  
for antidepressants without PA (21.4% vs. 24.2%) and atypical antipsychotics 
without PA (10.0% vs. 10.8%); the duloxetine initiation rate was not significantly 
different (2.9% vs. 2.7%). CONCLUSIONS: The Iowa Medicaid PA for duloxetine 
reduced the rate of duloxetine initiations, and did not increase atypical 
antipsychotic use.  
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IDENTIFYING SCHIZOPHRENIA PATIENTS AT HIGH-RISK FOR ANTIPSYCHOTIC 
NONADHERENCE USING THE ASSESSMENT FOR QUALITY IMPROVEMENT AND 
RISK EVALUATION TOOL  
Muser E1, Slabaugh SL2, Louder A2, Patel N3 
1Janssen Scientific Affairs, LLC, O'Fallon, MO, USA, 2Competitive Health Analytics, Inc., 
Louisville, KY, USA, 3Competitive Health Analytics, LLC, Louisville, KY, USA  
OBJECTIVES: Compare antipsychotic adherence and costs among patients with 
schizophrenia identified as “high-risk” for future antipsychotic nonadherence by 
the Assessment for Quality Improvement and Risk Evaluation (QI-RE) tool to 
controls not identified as high-risk. QI-RE is a software tool developed by Janssen 
Scientific Affairs, LLC and Boston Health Economics, Inc. that applies adapted 
published regression equations to pharmacy and medical claims data to assess 
schizophrenic patients’ risk for future antipsychotic nonadherence. METHODS: 
Retrospective analysis using pharmacy, medical, and eligibility data from 
Humana Medicare Advantage patients diagnosed with schizophrenia (ICD-9-CM 
295.xx) having continuous enrollment from 1/1/2010-12/31/2011. QI-RE and data 
from 2010 were used to identify patients in the highest-risk quartile for future 
antipsychotic nonadherence (high-risk cohort). The remaining patients in the 
study population (lower-risk) acted as the control cohort. Antipsychotic 
adherence (proportion of days covered [PDC]), persistence (14 day gap allowance) 
and health care costs during 2011 were compared across both cohorts. Student’s 
t-tests and chi-square tests were used for continuous and categorical variables, 
respectively. RESULTS: Relative to the control cohort (n=3,867), the high-risk 
cohort (n=1,139) was younger (mean age 54.6 vs. 55.4 years, p<0.041) and had 
more African Americans (26.0% vs. 17.8%, p<0.001). During follow-up, mean PDC 
was 0.48 versus 0.81 (p<0.001); persistence was 119.3 versus 144.3 days (p<0.001); 
antipsychotic pharmacy costs were $1,950 versus $3,933 (p<0.001); and, 
psychiatric-related medical costs were $4,938 versus $4,452 (p=0.192) for high-
risk and control cohorts, respectively. CONCLUSIONS: Patients identified as 
high-risk for antipsychotic nonadherence by QI-RE had poorer adherence, 
shorter persistency, and lower antipsychotic pharmacy costs during the follow-
up period relative to controls. These results support the potential utility of QI-RE 
for quality improvement initiatives related to antipsychotic adherence in 
patients with schizophrenia.  
 
PMH75  
IDENTIFYING SCHIZOPHRENIA PATIENTS AT HIGH-RISK FOR 
HOSPITALIZATION USING THE ASSESSMENT FOR QUALITY IMPROVEMENT 
AND RISK EVALUATION TOOL  
Slabaugh SL1, Louder A1, Patel N2, Muser E3 
1Competitive Health Analytics, Inc., Louisville, KY, USA, 2Competitive Health Analytics, LLC, 
Louisville, KY, USA, 3Janssen Scientific Affairs, LLC, O'Fallon, MO, USA  
OBJECTIVES: Examine hospitalization rates and costs for cohorts of patients with 
schizophrenia identified as ‘high-risk’ by the Assessment for Quality Improvement 
and Risk Evaluation (QI-RE) tool compared to cohorts not designated as ‘high-risk’. 
QI-RE is a software tool developed by Janssen Scientific Affairs, LLC and Boston 
Health Economics, Inc. that applies adapted published regression equations to 
pharmacy and medical claims to assess patients’ risk for future hospitalizations. 
METHODS: Retrospective analysis using pharmacy, medical, and eligibility claims 
data from Humana Medicare Advantage patients diagnosed with schizophrenia 
(ICD-9-CM 295.xx) having continuous enrollment from 1/1/2010-12/31/2011. QI-RE 
and data from 2010 were used to identify cohorts of patients in the highest-risk 
quartiles for future All-Cause (ACH) and Psychiatric-Related (PRH) hospitalization. 
For each hospitalization outcome, separate control cohorts were constructed with 
patients from the three lower-risk quartiles. Hospitalizations and costs during 1-
year follow-up (2011) were compared between high-risk and control cohorts. 
RESULTS: High-risk cohorts had a higher proportion of females (58.0% vs. 48.6% in 
ACH, p<.0001; 57.6% vs. 48.7% in PRH, p<.0001) and Caucasians (77.6% vs. 72.4% in 
ACH, p=.0042; 77.5% vs. 72.4% in PRH, p=.0048) relative to respective controls. During 
follow-up, the proportion with ≥1 hospitalization (56.5% vs. 26.0% in ACH, p<.0001; 
49.7% vs. 21.7% in PRH, p<.0001), mean number of hospitalizations (2.7 vs. 1.0 in 
ACH, p<.0001; 1.7 vs. 0.6 in PRH, p<.0001), and mean total health care costs ($23,203 
vs. $12,841 in ACH, p<.0001; $23,213 vs. $12,835 in PRH, p<.0001) were significantly 
higher for each QI-RE cohort relative to respective controls. CONCLUSIONS: Patients 
identified as high-risk by QI-RE experienced higher rates of hospitalizations and 
higher health care costs in the follow-up period relative to controls. These results 
support the potential utility of this population health tool for quality improvement 
and cost avoidance efforts in managing patients with schizophrenia.  
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CHARACTERISTICS OF ADULT MEDICAID BENEFICIARIES WITH 
SCHIZOPHRENIA TREATED WITH PALIPERIDONE PALMITATE AND PREDICTORS 
OF TREATMENT CONTINUITY  
Maiese BA1, Montejano LB1, Smith DM2, Clancy Z3, Pesa JA3 
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Bethesda, MD, USA, 
3Janssen Scientific Affairs, LLC, Titusville, NJ, USA  
OBJECTIVES: To describe characteristics of adult Medicaid beneficiaries with 
schizophrenia initiated with Paliperidone Palmitate (PP) and assess the 
relationships between such characteristics and treatment continuity. METHODS: 
Adult Medicaid enrollees with schizophrenia, 30+ days of treatment with PP, and 
6 months continuous enrollment prior to the first PP claim in 2009-2011 were 
identified in the MarketScan® Medicaid Multi-State Database. Exclusion criteria 
included dual eligible coverage, mental health carve-out, or a claim for Risperdal 
Consta at index. Characteristics were compared between three groups created 
based on days continuous with PP (Group A: ≥151, B: 91-150, C: 31-90). The first 
gap of 14+ days between the days covered by one claim and the date of the next 
claim was defined as the end of continuous therapy. Cox proportional hazards 
regression identified factors associated with PP treatment continuity over 6 
months. RESULTS: A total of 725 patients comprised the sample, of which 339 
(47%) were continuous with PP for ≥151 days. Overall, the average age for the 
sample was 39 years, 64% were male, 41% white. Pre-index characteristics for 
groups A vs C were significantly different with respect to the number of unique 
3-digit ICD-9 diagnosis codes (mean/SD: 8.8/7.3 vs 10.8/8.9; p=0.004), number of 
unique psychiatric diagnostic categories (2.8/2.0 vs 3.5/2.2; p<0.001), number of 
unique antipsychotic agents (1.6/1.0 vs 1.8/1.1; p=0.028), diagnosed bipolar 
disorder (17% vs 27%; p=0.003), diagnosed depression (20% vs 30%; p=0.006), 
diagnosed alcohol abuse (9% vs 15%; p=0.029) and percent of patients with any 
psychiatric hospitalization (30% vs 42%; p=0.002). Cox proportional hazards 
regression models (saturated & stepwise) did not identify any factors 
significantly associated with treatment continuity. CONCLUSIONS: Relative to 
patients continuous with PP therapy for longer than 151 days, patients with 31-
90 days of continuous therapy had a more complex profile of mental health 
comorbidites and pre-index resource utilization.  
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PIH1  
DRUG INTERACTIONS IN ELDERLY POPULATION IN PRIMARY HEALTH CARE  
Tomic N, Sabo A, Milijasevic B, Vukmirovic S 
Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro  
OBJECTIVES: Was to determine the percentage of drug interactions’ risk in 
elderly population receiving three or more drugs at the same time, also and 
degree of risk of severe, moderate and mild interactions. METHODS: This study 
was retrospectively-observational. The study included 50 patients of both 
genders, aged at least 65 years, who were treated in the first half 2012th in the 
Health Center Novi Sad which prescribed three or more drugs. Three sources of 
information about possible drug interactions were used: www.drugs.com, British 
National Formulary (BNF) and SPC of drug. RESULTS: The study included a total 
of 50 patients with mean age of 73.62 years. According to the number of possible 
drug interactions, most of them were from BNF (n = 204 or 45.43% compared to 
the number of possible drug combinations), then www.drugs.com (n = 203 or 
45.21%) and from SPC source were significantly less (n = 150 or 33.40%). In 
relation to the degree of relevancy of drug interactions, according to the source 
www.drugs.com, the incidence of serious interactions was 3%, 29% moderate 
and 13% mild. Out of 50 patients analyzed, only in 9 patients (18%) were found 
complete compatibility in the number of interactions in all three data sources. A 
significantly higher number of interactions were at the level of 
pharmacodynamic (167 or 77.68%). CONCLUSIONS: With the increasing number 
of taken drugs at the same time, increases the total number of interactions with 
a correlation coefficient of 0.71. Publications and Internet could provide useful 
information of drug interactions, but we could not say what else is important in 
a particular patient. This research was supported by Provincial Secretariat for 
Science and Technological Development, Autonomous Province of Vojvodina 
project No 114-451-2458/2011 and by Ministry of Science and Technological 
Development, Republic of Serbia project No 41012.  
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TERTIARY CARE SETTING  
Tiwari P1, Pipalava P2 
1National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. NAGAR, India, 
2NIPER, SAS NAGAR, India  
BACKGROUND: Medication errors is a major issue that every health care setting 
keeps addressing because it has a direct bearing on the safety of the patients. 
The results across the globe have demonstrated that the drug interactions 
continue to be a leading cause of errors. OBJECTIVES: The stduy was carried out 
with the obejctive of detecting the medication errors in the inpatients and profile 
them. METHODS: This study was carried out in an inpatient setting of a private 
tertiary care hospital. Medication errors were identified from patients' files, 
using Micromedex on PDA. 17 errors were fixed as the becnmark and 
assessments were done using this. RESULTS: The results are based on data 
